August 16, 2017 10:25 AM ET

Biotechnology

Company Overview of Biovest International Inc.

Company Overview

Biovest International, Inc., a biotechnology company, develops therapeutic cancer vaccines in the United States. It operates in two segments, Instrumentation and Vaccine. The company develops and commercializes BiovaxID, a personalized therapeutic cancer vaccine for the treatment of B-cell blood cancers. It is also involved in the development, manufacture, and sale of instruments and disposables, including AutovaxID, an automated cell culture system that enables production of personalized cell-based treatments; HF Primer, a cell culture system for producing small quantities of the cell culture products from mammalian cell lines; and Multi-6, a cell culture system for producing small scale qu...

300 South Hyde Park Avenue

Suite 210

Tampa, FL 33606

United States

Founded in 1981

41 Employees

Phone:

813-864-2554

Fax:

813-258-6912

Key Executives for Biovest International Inc.

Chief Executive Officer and President
Age: 40
Executive Chairman
Age: 70
Chief Medical Officer
Director of Legal Affairs and Corporate Secretary
Compensation as of Fiscal Year 2017.

Biovest International Inc. Key Developments

SEC Revokes Registration Of Registered Securities Of Biovest International

An Administrative Law Judge has issued an Initial Decision of Default as to Biovest International Inc. The Initial Decision found that the company was issuer of securities registered pursuant to Section 12(g) of the Securities Exchange Act of 1934 (Exchange Act), and the company failed to comply with Section 13(a) of the Exchange Act and Exchange Act Rules 13a-1 and/or 13a-13 by not filing required periodic reports with the Securities and Exchange Commission (SEC). The Initial Decision finds these allegations to be true and revokes the registration of each class of the company’s registered securities, pursuant to Section 12(j) of the Securities Exchange Act of 1934.

SEC Orders Hearings On Registration Suspension Or Revocation Against Biovest International For Failure To Make Required Periodic Filings

Securities and Exchange Commission (SEC or the commission) instituted public administrative proceeding to determine whether to revoke or suspend for a period not exceeding twelve months the registration of each class of the securities of Biovest International Inc. for failure to make required periodic filings with the Commission. In this Order, the Division of Enforcement (Division) alleges that the company was delinquent in its required periodic filings with the Commission. In this proceeding, instituted pursuant to Exchange Act Section 12(j), a hearing will be scheduled before an Administrative Law Judge. At the hearing, the judge will hear evidence from the Division and the company to determine whether the allegations of the Division contained in the Order, which the Division alleges constitute failures to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 there under, are true. The judge in the proceeding will then determine whether the registrations pursuant to Exchange Act Section 12 of each class of the securities of the company should be revoked or suspended for a period not exceeding twelve months. The Commission ordered that the Administrative Law Judge in this proceeding issue an initial decision not later than 120 days from the date of service of the order instituting proceeding.

Aytu Bioscience, Inc. Enters into a Master Services Agreement with Biovest International, Inc

On October 8, 2015, Aytu Bioscience Inc. entered into a Master Services Agreement with Biovest International Inc., pursuant to which Biovest is to provide manufacturing services to Aytu. The agreement provides that Aytu may engage Biovest from time to time to provide services in accordance with mutually agreed upon project addendums and purchase orders. The agreement provides customary terms and conditions, including those for performance of services by Biovest in compliance with project addendums, industry standards, regulatory standards and all applicable laws. Biovest will be responsible for obtaining and maintaining all governmental approvals, at Aytu's expense, during the term of the agreement. The agreement has a term of four years, provided that either party may terminate the agreement or any project addendum under the agreement on 30 days written notice of a material breach under the agreement. In addition, Aytu may terminate the agreement or any project addendum under the agreement upon 180 days written notice for any reason.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Biovest International Inc., please visit www.biovest.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.